文献速递产科母胎医学

分娩前已接受硫酸镁治疗的女性产后继续使用硫酸镁是否有益?一项随机对照研究

Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study.
PubMed 文献 · BJOG · 2018-07-11

本研究为拉丁美洲多中心随机对照试验,纳入分娩前已接受至少8小时硫酸镁治疗的1113例重度子痫前期女性,比较产后继续输注硫酸镁24小时与分娩后立即停药。结果显示两组子痫发生率及母体并发症无差异,停药组开始下床活动和开始泌乳的时间均显著更短。

要点

  • 分娩前已用硫酸镁至少8小时的重度子痫前期女性,产后继续用药24小时未降低子痫发生率。
  • 继续用药组子痫1/555(0.18%),停药组2/558(0.35%),RR 0.7(95%CI 0.1-3.3;P=0.50)。
  • 停药组开始下床活动与开始泌乳时间均显著短于继续用药组(P=0.0001)。

核心结论

  • 分娩前接受至少8小时硫酸镁治疗的重度子痫前期女性,产后继续使用硫酸镁24小时并无获益。

研究设计与样本

  • 随机多中心对照试验,在拉丁美洲开展,共随机1113例重度子痫前期女性。
  • 555例随机至产后继续输注硫酸镁24小时,558例随机至分娩后立即停止输注。
  • 入组女性分娩前均已接受4 g负荷剂量,随后以每小时1 g维持8小时。

主要发现

  • 子痫发生率:继续用药组1/555(0.18%)vs 停药组2/558(0.35%),RR 0.7(95%CI 0.1-3.3;P=0.50)。
  • 母体并发症两组间无差异,RR 1.0(95%CI 0.8-1.2;P=0.76)。
  • 开始下床活动时间停药组显著短于继续用药组(11.8±10.8小时 vs 18.1±10.6小时;P=0.0001)。
  • 开始泌乳时间停药组同样显著短于继续用药组(17.1±16.8小时 vs 24.1±17.1小时;P=0.0001)。
  • 随机分组时两组母体特征无差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if the use of magnesium sulphate postdelivery reduces the risk of eclampsia in women with severe pre-eclampsia exposed to at least 8 hours of magnesium sulphate before delivery. DESIGN: Randomised multicentre controlled trial. SETTING: Latin America. POPULATION: Women with severe pre-eclampsia that had received a 4-g loading dose followed by 1 g per hour for 8 hours as maintenance dose before delivery. METHODS: In all, 1113 women were randomised; 555 women were randomised to continue the infusion of magnesium sulphate for 24 hours postpartum and 558 were randomised to stopping the magnesium sulphate infusion immediately after delivery. OUTCOME MEASURES: Primary outcome was the incidence of eclampsia in the first 24 hours postdelivery. Secondary outcomes included maternal death, maternal complications, time to start ambulation and time to start lactation. RESULTS: The maternal characteristics at randomisation between the groups were not different. There were no differences in the rate of eclampsia; 1/555 (0.18%) versus 2/558 (0.35%) [relative risk (RR 0.7, 95% CI 0.1-3.3; P = 0.50] or maternal complications between the groups (RR 1.0, 95% CI 0.8-1.2; P = 0.76). Time to start ambulation was significantly shorter in the no magnesium sulphate group (18.1 ± 10.6 versus 11.8 ± 10.8 hours; P = 0.0001) and time to start lactation was equally shorter in the no magnesium sulphate group (24.1 ± 17.1 versus 17.1 ± 16.8 hours; P = 0.0001). CONCLUSIONS: Women with severe pre-eclampsia treated with a minimum of 8 hours of magnesium sulphate before delivery do not benefit from continuing the magnesium sulphate for 24 hours postpartum. TWEETABLE ABSTRACT: No benefit of continuing magnesium sulphate postpartum in severe pre-eclampsia exposed to this drug for a minimum of 8 hours before delivery.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Vigil-DeGracia P, Ludmir J, Ng J, et al. Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study. BJOG. 2018. PMID: 29878650. doi:10.1111/1471-0528.15320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。